Karin von Wachenfeldt

Karin von Wachenfeldt is the CEO of Truly Labs and the Interim CEO of Amplio Pharma AB, a company focused on developing improved versions of existing drugs. Karin is also the CEO and Co-founder of Truly Translational Sweden AB, providing expert scientific and strategic consulting services. Karin has extensive experience in the pharmaceutical industry, having worked as a Principal Scientist at AstraZeneca R&D, as well as in similar roles at Active Biotech, Pharmacia & Upjohn, and Ixsys Inc. Karin holds a Ph.D. in Immunotechnology from The Faculty of Engineering at Lund University and a B.Sc. in Biology and Chemistry from Lund University. Their early career at BioInvent International AB focused on basic immunology to enhance antibody generation processes.